Prosultiamine for treatment of lower urinary tract dysfunction accompanied by human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis.

about

Prosultiamine for treatment of lower urinary tract dysfunction accompanied by human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis.

Item

http://www.wikidata.org/entity/Q41927250

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Prosultiamine for treatment of ...... /tropical spastic paraparesis.

@en

type

Item

label

Prosultiamine for treatment of ...... /tropical spastic paraparesis.

@en

prefLabel

Prosultiamine for treatment of ...... /tropical spastic paraparesis.

@en

P1476

Prosultiamine for treatment of ...... /tropical spastic paraparesis.

@en

P2093

Hideki Sakai

http://www.w3.org/2001/XMLSchema#string

Katsuya Satoh

http://www.w3.org/2001/XMLSchema#string

Tatsufumi Nakamura

http://www.w3.org/2001/XMLSchema#string

Tomohiro Matsuo

http://www.w3.org/2001/XMLSchema#string

Yasuyoshi Miyata

http://www.w3.org/2001/XMLSchema#string

P2860

Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma

Nocturia Frequency, Bother, and Quality of Life: How Often Is Too Often? A Population-Based Study in Finland

Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

Urinary nerve growth factor: a biomarker of detrusor overactivity? A systematic review.

The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy.

The use of biomarkers in the diagnosis and treatment of overactive bladder: Can we predict the patients who will be resistant to treatment?

Urinary symptoms associated with human T-cell lymphotropic virus type I infection: evidence of urinary manifestations in large group of HTLV-I carriers.

Urodynamic features of the voiding dysfunction in HTLV-1 infected individuals.

Corticosteroid therapy in TSP/HAM patients: the results from a 10 years open cohort.

P31

scholarly article

P356

10.1111/IJU.13468

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28965354

http://www.w3.org/2001/XMLSchema#string

P921

Human T-lymphotropic virus 1